CGT · 다발성 골수종

73개 · ADC 890 · Antibody 4071 · CGT 2714 · 다음 갱신 D-4 · 마지막 9월 2일

PopularRecently updatedCuratedMost trialsNeeds refreshORRLatestPhase 3FDA approved73 programs
CGTCurated CoreFDAJohnson & JohnsonApproved

ciltacabtagene autoleucel (Carvykti, cilta-cel, LCAR-B38M, JNJ-68284528)

Relapsed or refractory multiple myeloma · BCMA

#BCMA#CGT#Approved#FDA-approved#BioJungboMoa-pick+5
Trials 29Status Approved
CGTLimited DatastaleNational Cancer Institute (NCI)Phase 1

Anti-B Cell Maturation Antigen (BCMA, Anti-B Cell Maturation Antigen, Anti-B Cell Maturation Antigen (BCMA) chimeric antigen receptors (CARs) T cells)

Myeloma-Multiple; Myeloma, Plasma-Cell · BCMA

#BCMA#CGT#Phase1#Popular#cell-gene-therapy+5
Trials 131Status Active
CGTStandard DatabasestaleMinsk Scientific-Practical Cent…Phase 2

Anti-BCMA CAR-T cells (Anti-BCMA CAR-T cells)

Multiple Myeloma Refractory · BCMA

#BCMA#CGT#Phase2#Popular#cell-gene-therapy+5
Trials 56Status Active
CGTLimited DatastaleSung-Soo ParkPreclinical

IMiD treatment (IMiD treatment)

Multiple Myeloma, Relapsed; Multiple Myeloma (MM) · FRα

#FR#CGT#Preclinical#cell-gene-therapy#CAR-T+5
Trials 39Status Recruiting
CGTLimited DatastaleHebei Senlang Biotechnology Inc…Phase 2

BCMA CAR-T (BCMA CAR-T)

Multiple Myeloma, Newly Diagnosed · BCMA

#BCMA#CGT#Phase2#cell-gene-therapy#CAR-T+4
Trials 35Status Recruiting
CGTLimited DatastaleChinese PLA General HospitalPhase 2

Anti-BCMA-CD19 CAR-T cells (Anti-BCMA-CD19 CAR-T cells)

IgG4 Related Disease; B-cell Mediated Autoimmune Disorders · CD19

#CD19#CGT#Phase2#cell-gene-therapy#CAR-T+5
Trials 30Status Recruiting
CGTLimited DatastaleThe First Affiliated Hospital o…Phase 1

Autologous BCMA CAR-T cells and CD19 CAR-T cells (Autologous BCMA CAR-T cells and CD19 CAR-T cells)

Relapsed or Refractory Multiple Myeloma · CD19

#CD19#CGT#Phase1#cell-gene-therapy#CAR-T+3
Trials 30Status Active
CGTStandard DatabasestaleHebei Senlang Biotechnology Inc…Phase 2

Autologous BCMA-targeting CAR T cells (Autologous BCMA-targeting CAR T cells)

Multiple Myeloma in Relapse; Multiple Myeloma Refractory · BCMA

#BCMA#CGT#Phase2#cell-gene-therapy#CAR-T+4
Trials 30Status Recruiting
CGTLimited DatastaleNanjing IASO Biotechnology Co.,…Phase 2

Eque-cel (Fully Human BCMA Chimeric Antigen Receptor Autologous T Cell Injection, Fully Human BCMA Chimeric Antigen Receptor Autologous T Cell Injection (Eque-cel))

Relapsed/Refractory Multiple Myeloma · BCMA

#BCMA#CGT#Phase2#cell-gene-therapy#CAR-T+4
Trials 9Status Recruiting
CGTStandard DatabasestaleThe First Hospital of Jilin Uni…Phase 2

IL-15-armored CAR-T cells (IL-15-armored CAR-T cells)

Relapsed/Refractory Multiple Myeloma; Plasma Cell Leukemia (PCL) · FRα

#FR#CGT#Phase2#cell-gene-therapy#CAR-T+5
Trials 8Status Recruiting
CGTLimited DatastaleShanghai AbelZeta Ltd.Phase 1

C-CAR088 (C-CAR088)

Relapsed or Refractory Multiple Myeloma · Multiple Myeloma

#MultipleMyeloma#CGT#Phase1#cell-gene-therapy#CAR-T+3
Trials 6Status Active
CGTLimited DatastaleiCell Gene TherapeuticsPhase 1

BCMA-CD19 cCAR T cells (BCMA-CD19 cCAR T cells)

Relapsed/Refractory, Systemic Lupus Erythematosus (SLE) · CD19

#CD19#CGT#Phase1#cell-gene-therapy#CAR-T+5
Trials 5Status Recruiting
CGTLimited DatastaleYake Biotechnology Ltd.Phase 1

APRIL CAR-T cells (APRIL CAR-T cells)

Multiple Myeloma in Relapse; Multiple Myeloma, Refractory · FRα

#FR#CGT#Phase1#cell-gene-therapy#CAR-T+5
Trials 4Status Recruiting
CGTLimited DatastalePolina StepenskyPhase 2

HBI0101 CART (HBI0101 CART)

Multiple Myeloma, Refractory to Standard Treatment; Multiple Myeloma, Relapsed · Systemic Sclerosis (SSc)

#SystemicSclerosisSSc#CGT#Phase2#cell-gene-therapy#CAR-T+5
Trials 4Status Recruiting
CGTLimited DatastaleCARsgen Therapeutics Co., Ltd.Phase 2

CAR-BCMA T Cells (CAR-BCMA T Cells)

Refractory or Relapsed Multiple Myeloma · BCMA

#BCMA#CGT#Phase2#cell-gene-therapy#CAR-T+3
Trials 3Status Active
CGTLimited DatastaleBioray LaboratoriesPhase 2

BCMA-CART (BCMA-CART)

Multiple Myeloma · BCMA

#BCMA#CGT#Phase2#cell-gene-therapy#CAR-T+3
Trials 2Status Discontinued
CGTLimited DatastaleOriCell Therapeutics Co., Ltd.Phase 2

OriCAR-017 (OriCAR-017)

Relapsed and/or Refractory Multiple Myeloma · Neoplasms, Plasma Cell

#NeoplasmsPlasmaCell#CGT#Phase2#cell-gene-therapy#CAR-T+4
Trials 2Status Recruiting
CGTLimited DatastaleNational Cancer Institute (NCI)Phase 1

Anti-B-cell maturation antigen (BCMA, Anti-B-cell maturation antigen, Anti-B-cell maturation antigen (BCMA) chimeric antigen receptor (CAR) T cells)

Myeloma, Plasma-Cell; Myeloma-Multiple · BCMA

#BCMA#CGT#Phase1#cell-gene-therapy#CAR-T+5
Trials 1Status Active
CGTLimited Datastale920th Hospital of Joint Logisti…Phase 2

Anti-GPRC5D CAR-T cells infusion (Anti-GPRC5D CAR-T cells infusion)

Multiple Myeloma in Relapse; Multiple Myeloma, Refractory · GPRC5D

#GPRC5D#CGT#Phase2#cell-gene-therapy#CAR-T+5
Trials 1Status Active
CGTLimited DatastaleBristol-Myers SquibbPhase 1

Anti-Signaling lymphocytic activation molecule F7 (SLAMF7, Anti-Signaling lymphocytic activation molecule F7, Anti-Signaling lymphocytic activation molecule F7 (SLAMF7) chimeric antigen receptor (CAR) T cells)

Myeloma-Multiple; Myeloma, Plasma-Cell · Myeloma-Multiple

#Myeloma-Multiple#CGT#Phase1#cell-gene-therapy#CAR-T+4
Trials 1Status Active

1 / 4 pages

← PreviousNext →